News & Updates

Pre-symptomatic diagnosis and treatment: A game changer for SMA

28 Feb 2025 by

Spinal muscular atrophy (SMA) is a progressive neurodegenerative disease that typically begins to manifest in infancy or childhood. Early diagnosis and prompt treatment before symptom onset can significantly improve clinical outcomes, including survival and attainment of motor milestones. At an industry-sponsored symposium co-organized by the Hong Kong Society of Neuromuscular Diseases (HKSNMD), Dr Astrid Blaschek of Dr von Hauner Children's Hospital in Munich, Germany, discussed implementation of the genetic newborn screening (NBS) programme for SMA in Germany and her clinical experience in managing children with SMA with available disease-modifying therapies, including risdiplam.

Pre-symptomatic diagnosis and treatment: A game changer for SMA

28 Feb 2025

Migraine: Rimegepant as dual treatment heralds a new paradigm

09 Feb 2025

Rimegepant, an oral calcitonin gene–related peptide (CGRP)–targeted therapy indicated for both acute and preventive treatment of migraine, heralds a new paradigm in long-term management of the condition.

Migraine: Rimegepant as dual treatment heralds a new paradigm

09 Feb 2025

CTAD 2024: Origin of lecanemab and real-world experience in its use

20 Jan 2025 by

At the Clinical Trials on Alzheimer’s Disease (CTAD) 2024 Conference held in Madrid, Spain, researchers from the US and Japan shared real-world clinical experience with lecanemab, the first approved disease-modifying treatment for early Alzheimer’s disease (AD). Professor Lars Lannfelt of Uppsala University, Sweden, who received the CTAD Lifetime Achievement Award in recognition of his pioneering work that led to the development of the monoclonal antibody (mAb) drug, described the origins of his ground-breaking discovery.

CTAD 2024: Origin of lecanemab and real-world experience in its use

20 Jan 2025

AAIC 2024: Early Alzheimer’s disease patients reap sustained benefits from long-term lecanemab treatment

09 Dec 2024 by

At the Alzheimer’s Association International Conference (AAIC) 2024 held in Philadelphia, US, researchers presented latest findings on the use of the dual-acting, anti–amyloid beta (Aβ) protofibril antibody, lecanemab, for treatment of early Alzheimer’s disease (AD). Topics covered included the paradoxical brain volume changes associated with anti-amyloid immunotherapy and the 3-year clinical efficacy results of continuous lecanemab treatment from the phase III Clarity AD study.

AAIC 2024: Early Alzheimer’s disease patients reap sustained benefits from long-term lecanemab treatment

09 Dec 2024

Real-world Chinese data: Rimegepant effective, well tolerated in acute Tx of migraine

18 Nov 2024

Rimegepant as acute therapy is effective and well tolerated in real-world Chinese patients with migraine, including those with very-high-frequency migraine (VHFM) days, prior nonresponders (PNRs) to any acute or preventive migraine treatment, and those on concomitant eptinezumab as preventive treatment, a study in China has shown.

Real-world Chinese data: Rimegepant effective, well tolerated in acute Tx of migraine

18 Nov 2024

[Infographics] Rimegepant for acute and preventive migraine management: Why?

17 Oct 2024

How does rimegepant, an oral CGRP-targeted therapy indicated for both acute and preventive treatment of migraine, address gaps in migraine management?

[Infographics] Rimegepant for acute and preventive migraine management: Why?

17 Oct 2024

Acute and preventive migraine management with CGRP-targeted therapies

16 Oct 2024 by

At an industry-sponsored meeting during the 10^thCongress of the European Academy of Neurology (EAN 2024), Professor Marja-Liisa Sumelahti of Tampere University in Tampere, Finland, Dr Roni Sharon of the Tel Aviv University in Tel Aviv, Israel, and Dr Margarita Sánchez del Rio of the Clínica Universidad de Navarra in Madrid, Spain, discussed the role of calcitonin gene-related peptide (CGRP)–targeted agents, specifically the oral CGRP receptor antagonist (RA), rimegepant, in early migraine management.

Acute and preventive migraine management with CGRP-targeted therapies

16 Oct 2024

Rimegepant shows favourable safety & tolerability in migraine patients with CV risk factors

15 Oct 2024

In migraine patients with cardiovascular (CV) risk factors, including those with moderate to high CV risk, rimegepant for long-term acute treatment of migraine is associated with favourable safety and tolerability, post hoc subgroup analyses of a 52-week multicentre open-label safety study have shown.

Rimegepant shows favourable safety & tolerability in migraine patients with CV risk factors

15 Oct 2024

Rimegepant for long-term acute Tx of migraine cuts monthly attack days, shows no MOH signal

24 Sep 2024

In patients with ≥1 year’s history of migraine and ≥6 monthly migraine days (MMDs), acute treatment of migraine with rimegepant 75 mg up to once daily as needed for up to 52 weeks is associated with reduced MMDs, with no increase in monthly tablet utilization and no evidence of medication overuse headache (MOH), a post hoc analysis of an open-label safety study has shown.

Rimegepant for long-term acute Tx of migraine cuts monthly attack days, shows no MOH signal

24 Sep 2024

Rimegepant shows favourable safety and tolerability in long-term acute migraine treatment

20 Sep 2024

Rimegepant, taken for up to 1 year for acute treatment of migraine, is well tolerated with no signal of hepatotoxicity, a recent study has shown.

Rimegepant shows favourable safety and tolerability in long-term acute migraine treatment

20 Sep 2024

News & Updates

Filter by Specialty:

Specialty:

Pre-symptomatic diagnosis and treatment: A game changer for SMA

Pre-symptomatic diagnosis and treatment: A game changer for SMA

Migraine: Rimegepant as dual treatment heralds a new paradigm

Migraine: Rimegepant as dual treatment heralds a new paradigm

CTAD 2024: Origin of lecanemab and real-world experience in its use

CTAD 2024: Origin of lecanemab and real-world experience in its use

AAIC 2024: Early Alzheimer’s disease patients reap sustained benefits from long-term lecanemab treatment

AAIC 2024: Early Alzheimer’s disease patients reap sustained benefits from long-term lecanemab treatment

Real-world Chinese data: Rimegepant effective, well tolerated in acute Tx of migraine

Real-world Chinese data: Rimegepant effective, well tolerated in acute Tx of migraine

[Infographics] Rimegepant for acute and preventive migraine management: Why?

[Infographics] Rimegepant for acute and preventive migraine management: Why?

Acute and preventive migraine management with CGRP-targeted therapies

Acute and preventive migraine management with CGRP-targeted therapies

Rimegepant shows favourable safety & tolerability in migraine patients with CV risk factors

Rimegepant shows favourable safety & tolerability in migraine patients with CV risk factors

Rimegepant for long-term acute Tx of migraine cuts monthly attack days, shows no MOH signal

Rimegepant for long-term acute Tx of migraine cuts monthly attack days, shows no MOH signal

Rimegepant shows favourable safety and tolerability in long-term acute migraine treatment

Rimegepant shows favourable safety and tolerability in long-term acute migraine treatment